Dr. Pouya Dayani, M.D.
What this data tells you about Dr. Dayani
Dr. Pouya Dayani is an ophthalmology specialist in Los Angeles, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Dayani performed 37,262 Medicare services across 4,962 unique beneficiaries.
Between the years covered by Open Payments, Dr. Dayani received a total of $86,581 from 21 pharmaceutical and/or device companies across 205 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in ophthalmology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Dayani is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Eye injection (Vabysmo/faricimab) An injection of faricimab-svoa, a medication administered in 0.1 mg doses. |
23,640 | $29 | $85 |
| Comprehensive eye exam, established patient A comprehensive examination of the visual system performed for a patient who has previously been seen by the provider. |
2,975 | $105 | $300 |
| Retinal imaging (OCT scan) This procedure involves imaging the retina to visualize its structure. It is used to examine the back of the eye. |
2,916 | $34 | $150 |
| Eye injection for retinal disease A procedure involving the administration of medication directly into the eye. |
1,406 | $103 | $728 |
| Ranibizumab-eqrn injection, 0.1 mg An injection of the biosimilar medication ranibizumab-eqrn (Cimerli) in a 0.1 mg dose. |
1,353 | $219 | $700 |
| Aflibercept eye injection (Eylea) | 1,050 | $687 | $2,500 |
| Extended exam of back of eye with optic nerve drawing A detailed examination of the posterior section of the eye, including the optic nerve, with documentation through drawing. |
885 | $12 | $170 |
| Extended eye exam with retinal drawing A detailed examination of the back of the eye that includes creating a drawing of the retina. |
627 | $19 | $170 |
| Retinal photography (fundus photo) This procedure involves taking photographs of the retina, the light-sensitive tissue at the back of the eye. It is used to document the condition of the eye's interior structures. |
603 | $31 | $115 |
| Injection, ranibizumab, 0.1 mg | 376 | $178 | $1,000 |
| Dexamethasone intravitreal implant injection An injection of a dexamethasone implant placed inside the eye. This procedure delivers medication directly into the vitreous cavity of the eye. |
266 | $157 | $250 |
| Ultrasound of eye tissue and structures A diagnostic imaging test that uses sound waves to create pictures of the eye's internal tissues and structures. |
258 | $39 | $200 |
| Retinal angiography with dye injection This procedure uses a special camera to examine the blood vessels in the retina after a dye has been injected into the body. |
217 | $123 | $275 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
150 | $119 | $300 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
101 | $95 | $150 |
| Bevacizumab injection, 10 mg Administration of a 10 mg dose of bevacizumab medication via injection. |
98 | $53 | $200 |
| Eye exam, established patient, focused A limited examination of the visual system for an existing patient. The provider focuses on a specific eye-related concern or symptom. |
97 | $81 | $200 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
77 | $155 | $280 |
| New patient office visit, complex (60-74 min) | 72 | $172 | $375 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
59 | $1,433 | $4,508 |
| Retinal membrane and internal limiting membrane removal A surgical procedure to remove a membrane from the retina along with the internal limiting membrane of the retina. |
12 | $960 | $6,200 |
| Retinal photocoagulation to prevent detachment This procedure uses laser light to create small burns on the retina. It is performed to help prevent the retina from detaching from the back of the eye. |
12 | $172 | $1,650 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
12 | $73 | $125 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
All-time payments by company (2018-2024) ›
Associated products mentioned in payments ›
The majority of payments (50%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in ophthalmology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 5% for ophthalmology in CA.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Dayani is a mixed practice specialist, with above-average Medicare volume (top 2% in CA), with speaking/promotional industry engagement in the top 5% of CA peers, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Dayani experienced with eye injection (vabysmo/faricimab)?
Does Dr. Dayani receive payments from pharmaceutical companies?
How do Dr. Dayani's costs compare to other ophthalmologists in Los Angeles?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology